Phospho-CCNC (Ser275) Antibody

What is the function of Cyclin C and the significance of its Ser275 phosphorylation?

Cyclin C functions as a component of the Mediator complex, which is involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. It acts as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. When Cyclin C binds to and activates cyclin-dependent kinase CDK8, it induces the phosphorylation of the C-terminal domain (CTD) of the large subunit of RNA polymerase II, which may inhibit the formation of the transcription preinitiation complex .

Phosphorylation at Ser275 occurs in the region spanning amino acids 234-283 of human Cyclin C. While the exact functional significance of this specific phosphorylation site requires further research, it likely plays a role in regulating Cyclin C's interaction with other components of the transcriptional machinery. The phosphorylation status can be specifically detected using antibodies that recognize this phospho-epitope.

What applications are Phospho-CCNC (Ser275) antibodies validated for?

Phospho-CCNC (Ser275) antibodies have been validated for multiple research applications:

The discrepancy between observed and calculated molecular weights is likely due to post-translational modifications affecting protein migration in SDS-PAGE .

How should researchers store and handle Phospho-CCNC (Ser275) antibodies for optimal performance?

For optimal antibody performance, follow these storage and handling guidelines:

• Long-term storage: Store at -20°C for up to 1 year from receipt date

• Short-term storage: For frequent use, store at 4°C for up to one month

• Formulation: Typically provided in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

• Avoid repeated freeze-thaw cycles by aliquoting the antibody upon receipt

• When working with the antibody, keep it cold and protect from light

• Always centrifuge briefly before opening the vial to ensure all liquid is at the bottom

Improper storage can lead to decreased activity, increased background, or reduced specificity over time.

What methods can be used to validate the specificity of Phospho-CCNC (Ser275) antibodies?

Rigorous validation of phospho-specific antibodies is essential for ensuring reliable experimental results. Implement these methodological approaches:

• Phosphatase treatment validation:

  • Treat samples with λ-phosphatase to remove phosphate groups

  • Compare untreated vs. phosphatase-treated samples by Western blot or immunofluorescence

  • A true phospho-specific antibody will show significantly reduced or eliminated signal in phosphatase-treated samples

• Peptide competition assay:

  • Pre-incubate the antibody with excess phosphopeptide immunogen

  • In parallel, pre-incubate with non-phosphorylated peptide of the same sequence

  • The phosphopeptide should abolish signal while non-phosphopeptide should have minimal effect

• Mutagenesis approach:

  • Generate a Ser275Ala mutant of CCNC that cannot be phosphorylated at position 275

  • Express both wild-type and mutant in cells

  • The antibody should detect wild-type but not the Ser275Ala mutant

• Knockdown/knockout validation:

  • Reduce CCNC expression using siRNA or CRISPR techniques

  • Confirm successful knockdown with antibodies against total CCNC

  • The phospho-specific signal should decrease proportionally to total protein reduction

• Cross-reactivity assessment:

  • Test against closely related proteins with similar phosphorylation motifs

  • Evaluate species cross-reactivity if working with non-human samples

What are the optimal sample preparation methods for preserving phosphorylation when using Phospho-CCNC (Ser275) antibodies?

Phosphorylation states can be rapidly lost during sample preparation. Follow these methodological guidelines:

For cell/tissue lysate preparation:

• Use ice-cold buffers containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

• Include protease inhibitor cocktail to prevent protein degradation

• Lyse cells directly in SDS sample buffer for immediate denaturation when possible

• Process samples quickly and keep them cold throughout preparation

• For western blotting, use freshly prepared samples when possible, or snap-freeze aliquots

For immunohistochemistry/immunofluorescence:

• Fix tissues rapidly after collection (within minutes if possible)

• Use phosphatase inhibitors in washing buffers

• Consider using phospho-specific fixatives (e.g., containing phosphatase inhibitors)

• Optimize fixation time to prevent overfixation which can mask epitopes

• Test different antigen retrieval methods (citrate buffer pH 6.0 or EDTA buffer pH 8.0)

For chromatin immunoprecipitation (ChIP):

• Include phosphatase inhibitors in all buffers

• Perform cross-linking quickly after cell harvesting

• Use fresh samples whenever possible

How can researchers develop high-quality phospho-specific antibodies like Phospho-CCNC (Ser275)?

Several methodological approaches exist for generating phospho-specific antibodies:

• Classical peptide immunization method:

  • Design a synthetic phosphopeptide spanning the region of interest (e.g., aa 234-283 for CCNC)

  • Conjugate to carrier protein (typically KLH) for immunization

  • Immunize rabbits or other host animals

  • Purify antibodies using affinity chromatography with phosphopeptide

  • Remove non-phospho-specific antibodies by adsorption against the non-phosphorylated peptide

• Direct selection from full-length protein:

  • Express full-length protein in bacteria (e.g., His-tagged CCNC)

  • Phosphorylate in vitro using mitotic cell extracts or purified kinases

  • Use this phosphorylated protein as antigen for antibody selection

  • Select antibodies using phage display technology

  • This approach allows selection of antibodies recognizing the native conformation of the phosphoprotein

• Synthetic antibody library approach:

  • Create a synthetic antibody library by engineering the complementarity-determining regions (CDRs)

  • Incorporate phospho-binding motifs similar to those found in kinases

  • Select antibodies through phage display against specific phosphopeptides

  • This approach can generate antibodies with high specificity for subtle differences in phosphorylation patterns

The development process typically takes 2-4 months, with validation requiring additional time to ensure specificity across multiple applications .

What controls should be included when using Phospho-CCNC (Ser275) antibody in research experiments?

Proper controls are essential for interpreting results with phospho-specific antibodies:

Essential controls for all experiments:

• Positive control: Sample known to contain phosphorylated CCNC (e.g., mitotic cell extracts)

• Negative controls:

  • Phosphatase-treated sample

  • Sample expressing Ser275Ala mutant CCNC (cannot be phosphorylated)

  • CCNC-depleted sample (siRNA knockdown or knockout)

Application-specific controls:

Detailed documentation of all controls increases result reliability and helps troubleshoot if experiments fail .

How can Phospho-CCNC (Ser275) antibodies be used to study cell cycle-dependent phosphorylation dynamics?

Cyclin C mRNA levels peak during G1 phase of the cell cycle , but Ser275 phosphorylation dynamics may follow different patterns. To investigate this:

• Cell synchronization methodology:

  • Synchronize cells using established methods:

    • Double thymidine block (G1/S boundary)

    • Nocodazole treatment (M phase)

    • Serum starvation/stimulation (G0/G1)

  • Collect samples at regular intervals as cells progress through the cycle

• Multi-parameter analysis:

  • Western blot analysis: Compare phospho-CCNC levels to total CCNC

  • Include cell cycle markers (Cyclins A, B, D, E) to confirm synchronization

  • Quantify band intensities and normalize phospho-signal to total protein

• Single-cell methods:

  • Flow cytometry: Combine DNA content staining with intracellular phospho-CCNC staining

  • Immunofluorescence: Co-stain for phospho-CCNC and cell cycle markers

  • Live-cell imaging: If compatible antibody fragments are available, monitor dynamics in real time

• Kinase inhibition experiments:

  • Treat synchronized cells with inhibitors of cell cycle-regulated kinases

  • Monitor effects on Ser275 phosphorylation

  • This approach can help identify the responsible kinase(s)

• Phosphoproteome analysis:

  • Use mass spectrometry to quantify phosphorylation at Ser275 throughout the cell cycle

  • Compare with antibody-based detection methods

These approaches provide complementary data on when and how CCNC becomes phosphorylated during cell cycle progression.

What approaches can resolve apparent discrepancies in experimental data when using Phospho-CCNC (Ser275) antibodies?

When faced with conflicting or unexpected results, consider these methodological approaches:

• Antibody validation assessment:

  • Re-validate antibody specificity using phosphatase treatment

  • Test a different lot or source of phospho-specific antibody

  • Compare results with another detection method (e.g., mass spectrometry)

• Technical considerations:

  • Optimize protein extraction to preserve phosphorylation status

  • Test different blocking agents (BSA instead of milk for phosphoepitopes)

  • Adjust antibody concentration and incubation conditions

  • For Western blot, try different membrane types (PVDF vs. nitrocellulose)

• Biological variables:

  • Cell type differences in phosphorylation patterns

  • Culture conditions affecting kinase/phosphatase activities

  • Cell cycle status impacting phosphorylation levels

  • Stimulation conditions altering signaling cascades

• Molecular approaches:

  • Express wild-type and Ser275Ala mutant CCNC and compare

  • Use kinase inhibitors to confirm phosphorylation dependency

  • Employ CRISPR-Cas9 to tag endogenous CCNC for validation

• Quantification methods:

  • Use multiple normalization strategies

  • Apply statistical tests appropriate to the data distribution

  • Consider single-cell analysis if population heterogeneity is suspected

When reporting discrepancies, document all experimental conditions thoroughly to help others interpret the differences.

How can Phospho-CCNC (Ser275) antibodies be integrated into studies of transcriptional regulation and the Mediator complex?

The Mediator complex plays a crucial role in regulating RNA polymerase II-dependent transcription. Phospho-CCNC (Ser275) antibodies can be strategically employed in several sophisticated experimental designs:

• Chromatin Immunoprecipitation (ChIP) studies:

  • Use Phospho-CCNC (Ser275) antibodies for ChIP followed by sequencing (ChIP-seq)

  • Compare binding profiles of phosphorylated vs. total CCNC

  • Investigate co-occupancy with RNA Polymerase II and other Mediator components

  • Analyze whether phosphorylation status correlates with active or repressed genes

  • Methodology note: Include spike-in controls for quantitative comparisons

• Protein-protein interaction analysis:

  • Perform co-immunoprecipitation using Phospho-CCNC (Ser275) antibodies

  • Compare interactome differences between phosphorylated and non-phosphorylated CCNC

  • Use proximity ligation assays to visualize interactions in situ

  • Employ BioID or APEX2 proximity labeling with phospho-mutants to map interaction networks

• Functional transcription assays:

  • Correlate changes in Ser275 phosphorylation with transcriptional output

  • Measure nascent RNA synthesis (e.g., EU incorporation, PRO-seq)

  • Examine effects of phosphomimetic (S275D/E) and phospho-dead (S275A) mutations

  • Investigate whether CDK8 activity is regulated by CCNC phosphorylation status

• Structural studies:

  • Use antibodies for validation in structural biology approaches

  • Compare cryo-EM structures of Mediator complex with phosphorylated vs. non-phosphorylated CCNC

  • Investigate conformational changes induced by phosphorylation

• Signaling pathway integration:

  • Map kinase cascades leading to CCNC Ser275 phosphorylation

  • Determine how extracellular signals modulate this phosphorylation event

  • Connect Mediator complex activity to broader cellular signaling networks

What methodological approaches can distinguish between different phosphorylation states of CCNC in complex samples?

Distinguishing multiple phosphorylation states presents analytical challenges that require sophisticated methods:

• Multiplexed antibody approaches:

  • Develop a panel of antibodies against different phosphorylation sites on CCNC

  • Use multiplexed Western blotting with fluorescent secondary antibodies

  • Employ sequential immunoprecipitation to isolate specific phospho-forms

  • Methodology note: Test for antibody interference when using multiple phospho-specific antibodies

• Phospho-proteomic analysis:

  • Use titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC) to enrich phosphopeptides

  • Employ mass spectrometry to identify and quantify different phosphorylated residues

  • Apply parallel reaction monitoring (PRM) for targeted quantification of specific phosphopeptides

  • Compare results with antibody-based detection methods for cross-validation

• 2D phosphorylation mapping:

  • Separate proteins by isoelectric focusing followed by SDS-PAGE

  • Detect with total CCNC antibody to visualize different phospho-forms

  • Confirm specific spots with Phospho-CCNC (Ser275) antibody

  • Use phosphatase treatment to verify phosphorylation-dependent shifts

• Mobility shift assays:

  • Utilize Phos-tag™ SDS-PAGE to enhance separation of phosphorylated proteins

  • Compare migration patterns before and after phosphatase treatment

  • Combine with Western blotting using total and phospho-specific antibodies

• Single-molecule analysis:

  • Apply super-resolution microscopy with differentially labeled antibodies

  • Develop FRET-based sensors for detecting phosphorylation states

  • Use correlative light and electron microscopy (CLEM) for ultrastructural context

Each approach has specific advantages and limitations, making complementary methods necessary for comprehensive analysis.

How do novel antibody engineering approaches improve phospho-specific detection compared to traditional methods?

Recent advances in antibody engineering have significantly enhanced phospho-specific detection capabilities:

• Structure-based design improvements:

  • Integration of phosphate-binding motifs from kinases into antibody CDRs

  • Rational design of complementarity-determining regions to create optimal binding pockets

  • Computer-aided optimization of antibody-phosphoepitope interactions

  • These approaches generate antibodies with substantially higher specificity and affinity

• Phage display selection advantages:

  • Direct selection against full-length phosphorylated proteins

  • Multiple rounds of positive selection against phosphorylated targets

  • Negative selection against non-phosphorylated proteins to eliminate cross-reactivity

  • Results in antibodies recognizing conformation-specific phospho-epitopes with higher specificity

• Synthetic antibody libraries:

  • Libraries with billions of variants enable selection of rare high-specificity binders

  • Incorporation of unnatural amino acids for enhanced phosphate recognition

  • Design of scaffolds specifically optimized for phosphoepitope recognition

  • These approaches have generated antibodies targeting specific phosphorylation patterns on proteins like RNA polymerase II CTD

• Fragment-based approaches:

  • Development of smaller antibody fragments (scFvs, Fabs) with better tissue penetration

  • Engineering for enhanced stability and resistance to various buffer conditions

  • Creation of bispecific formats that simultaneously detect phosphorylation and total protein

  • These formats enable novel applications like intracellular real-time imaging

• Performance comparison:

These advances have significantly improved the reliability and utility of phospho-specific antibodies in research applications .